

ENGAGING PATIENTS IN A CONVERSATION ABOUT NALOXONE

WB4665R

PROGRAM DESCRIPTION: This enduring activity is designed to increase knowledge and change competency of clinicians on identifying patients at increased risk for opioid overdose and practices and strategies for offering naloxone.

OBJECTIVES:

At the conclusion of the activity, the participant will be able to:

1. Identify the key points to share with patients about risk of overdose when using opioids.
2. Identify how interprofessional care coordination to support offering of naloxone can reduce the risk of opioid overdose.

FACULTY/ CREDENTIALS:

Christina A. Mikosz, MD, MPH, Lead Medical Officer,
Division of Overdose Prevention, National Center for
Injury Prevention and Control (NCIPC), Centers for
Disease Control and Prevention
Molly Dowling, MPH, Health Communications
Specialist, Division of Overdose Prevention, National
Center for Injury Prevention and Control (NCIPC),
Centers for Disease Control and Prevention

CE ORIGATION DATE:

July 28, 2023

CE RENEWAL DATE:

July 28, 2025

CE EXPIRATION DATE:

July 28, 2027

URL

<https://www.cdc.gov/overdose-prevention/hcp/trainings/conversation-about-naloxone.html>

INTENDED AUDIENCE:

Physicians, Registered Nurses

PREREQUISITES:

None

FORMAT:

This activity is Web-based

CONTACT INFORMATION:

CDC's CE Accreditation Team has a policy for grievances that is available upon request.

Office of Division of Overdose Prevention, National Center for Injury Prevention and Control 800-232-4636

ACCREDITATION STATEMENTS:

JOINTLY ACCREDITED PROVIDER™
INTERPROFESSIONAL CONTINUING EDUCATION

In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this **enduring** activity for a maximum of **0.5** AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CNE: The Centers for Disease Control and Prevention designates this activity for **0.5** nursing contact hours.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies during the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and content experts wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, reselling, or distributing healthcare products used by or on patients.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.

The Centers for Disease Control and Prevention (CDC) complies with applicable Federal civil rights laws and does not discriminate based on race, color, national origin, age, disability, religion, or sex (including pregnancy, sexual orientation, and gender identity). To learn more visit: <https://www.hhs.gov/civil-rights/for-individuals/nondiscrimination/index.html>.

Instructions for Obtaining Continuing Education (CE)

To receive continuing education (CE) for **WB4665R Engaging Patients in a Conversation about Naloxone**, please visit [CDC TRAIN](#) and search for the course in the Course Catalog using **WB4665R**. Follow the steps below by **07/28/2027**.

1. Register for and complete the course.
2. Pass the post-assessment at **80%**.
3. Complete the evaluation.
4. Visit Your Learning to access your certificates and transcript.

FEES: No fees are charged for CDC's CE activities.